Development and Research of YS110

Substance under development stage in clinical study and pre-clinical research

YS110 : a humanized monoclonal antibody (IGg1) against CD26 molecule. YS110 has shown the anti-tumor activity in various types of CD26 positive tumor( a positivity of CD26 expression on human cancer cell membrane is shown), such as malignant mesothelioma, lung carcinoma, renal carcinoma, lymphoma, colorectal carcinoma, prostate carcinoma etc., in preclinical study. For example, the anti-tumor activity of YS110 in in vivo against malignant mesothelioma, ovarian carcinoma or lung carcinoma are shown. It is reported CD26 molecule is a cancer stem cell marker of malignant mesothelioma, colon cancer, and CML. The mechanisms of anti-tumor activity of YS110 have been investigated in the preclinical study and summarized.